Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications ...

Many dog owners have already heard about the FDA warning and seen the articles on the terrible side effects experienced by ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.